Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)

Hiromitsu Kumada; Tsunamasa Watanabe; Fumitaka Suzuki; Kenji Ikeda; Ken Sato; Hidenori Toyoda; Masanori Atsukawa; Akio Ido; Akinobu Takaki; Nobuyuki Enomoto; Koji Kato; Katia Alves; Margaret Burroughs; Rebecca Redman; David Pugatch; Tami J. Pilot-Matias; Preethi Krishnan; Rajneet K. Oberoi; Wangang Xie; Kazuaki Chayama

doi:10.1007/s00535-017-1409-z

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)

Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, Kenji Ikeda, Ken Sato, Hidenori Toyoda, Masanori Atsukawa, Akio Ido, Akinobu Takaki, Nobuyuki Enomoto, Koji Kato, Katia Alves, Margaret Burroughs, Rebecca Redman, David Pugatch, Tami J. Pilot-Matias, Preethi Krishnan, Rajneet K. Oberoi, Wangang Xie, Kazuaki Chayama

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “

Original language	English
Pages (from-to)	689
Number of pages	1
Journal	Journal of Gastroenterology
Volume	53
Issue number	5
DOIs	https://doi.org/10.1007/s00535-017-1409-z
Publication status	Published - May 1 2018

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1007/s00535-017-1409-z

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)'. Together they form a unique fingerprint.

Cite this

Kumada, H., Watanabe, T., Suzuki, F., Ikeda, K., Sato, K., Toyoda, H., Atsukawa, M., Ido, A., Takaki, A., Enomoto, N., Kato, K., Alves, K., Burroughs, M., Redman, R., Pugatch, D., Pilot-Matias, T. J., Krishnan, P., Oberoi, R. K., Xie, W., & Chayama, K. (2018). Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0). Journal of Gastroenterology, 53(5), 689. https://doi.org/10.1007/s00535-017-1409-z

Correction to : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0). / Kumada, Hiromitsu; Watanabe, Tsunamasa; Suzuki, Fumitaka et al.

In: Journal of Gastroenterology, Vol. 53, No. 5, 01.05.2018, p. 689.

Research output: Contribution to journal › Comment/debate › peer-review

Kumada, H, Watanabe, T, Suzuki, F, Ikeda, K, Sato, K, Toyoda, H, Atsukawa, M, Ido, A, Takaki, A, Enomoto, N, Kato, K, Alves, K, Burroughs, M, Redman, R, Pugatch, D, Pilot-Matias, TJ, Krishnan, P, Oberoi, RK, Xie, W & Chayama, K 2018, 'Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)', Journal of Gastroenterology, vol. 53, no. 5, pp. 689. https://doi.org/10.1007/s00535-017-1409-z

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H et al. Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0). Journal of Gastroenterology. 2018 May 1;53(5):689. doi: 10.1007/s00535-017-1409-z

Kumada, Hiromitsu ; Watanabe, Tsunamasa ; Suzuki, Fumitaka et al. / Correction to : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0). In: Journal of Gastroenterology. 2018 ; Vol. 53, No. 5. pp. 689.

@article{c48af1d779544941ba818e0386bc3330,

title = "Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)",

abstract = "Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “",

author = "Hiromitsu Kumada and Tsunamasa Watanabe and Fumitaka Suzuki and Kenji Ikeda and Ken Sato and Hidenori Toyoda and Masanori Atsukawa and Akio Ido and Akinobu Takaki and Nobuyuki Enomoto and Koji Kato and Katia Alves and Margaret Burroughs and Rebecca Redman and David Pugatch and Pilot-Matias, {Tami J.} and Preethi Krishnan and Oberoi, {Rajneet K.} and Wangang Xie and Kazuaki Chayama",

note = "Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2018",

month = may,

day = "1",

doi = "10.1007/s00535-017-1409-z",

language = "English",

volume = "53",

pages = "689",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Correction to

T2 - Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)

AU - Kumada, Hiromitsu

AU - Watanabe, Tsunamasa

AU - Suzuki, Fumitaka

AU - Ikeda, Kenji

AU - Sato, Ken

AU - Toyoda, Hidenori

AU - Atsukawa, Masanori

AU - Ido, Akio

AU - Takaki, Akinobu

AU - Enomoto, Nobuyuki

AU - Kato, Koji

AU - Alves, Katia

AU - Burroughs, Margaret

AU - Redman, Rebecca

AU - Pugatch, David

AU - Pilot-Matias, Tami J.

AU - Krishnan, Preethi

AU - Oberoi, Rajneet K.

AU - Xie, Wangang

AU - Chayama, Kazuaki

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “

AB - Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “

UR - http://www.scopus.com/inward/record.url?scp=85033603534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033603534&partnerID=8YFLogxK

U2 - 10.1007/s00535-017-1409-z

DO - 10.1007/s00535-017-1409-z

M3 - Comment/debate

C2 - 29134328

AN - SCOPUS:85033603534

VL - 53

SP - 689

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 5

ER -

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this